Sentiment-Signal
19,7
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
Unternehmen & Branche
| Name | NRX Pharmaceuticals, Inc. |
|---|---|
| Ticker | NRXP |
| CIK | 0001719406 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 51,3 Mio. USD |
| Beta | 1,83 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 1,225,000 | -28,622,000 | 12,956,000 | -15,937,000 | |
| 2025-09-30 | 10-Q | 242,000 | -5,890,000 | 14,996,000 | -25,755,000 | |
| 2025-06-30 | 10-Q | 0 | -17,581,000 | 4,838,000 | -35,615,000 | |
| 2025-03-31 | 10-Q | 0 | -5,512,000 | 7,590,000 | -25,161,000 | |
| 2024-12-31 | 10-K | 0 | -25,126,000 | 3,651,000 | -23,223,000 | |
| 2024-09-30 | 10-Q | 0 | -1,623,000 | 4,462,000 | -18,822,000 | |
| 2024-06-30 | 10-Q | 0 | -7,897,000 | 5,264,000 | -18,391,000 | |
| 2024-03-31 | 10-Q | -6,528,000 | -0.74 | 3,788,000 | -15,069,000 | |
| 2023-12-31 | 10-K | -30,150,000 | 7,315,000 | -11,733,000 | ||
| 2023-09-30 | 10-Q | -6,062,000 | -0.07 | 13,110,000 | -6,217,000 | |
| 2023-06-30 | 10-Q | -8,717,000 | -0.12 | 19,809,000 | -2,808,000 | |
| 2023-03-31 | 10-Q | -5,512,000 | -1.66 | 21,780,000 | -284,000 | |
| 2022-12-31 | 10-K | -39,754,000 | -0.60 | 25,816,000 | 7,409,000 | |
| 2022-09-30 | 10-Q | -9,083,000 | -0.14 | 24,824,000 | 16,782,000 | |
| 2022-06-30 | 10-Q | -6,982,000 | -0.11 | 32,433,000 | 25,352,000 | |
| 2022-03-31 | 10-Q | -13,448,000 | -0.21 | 43,601,000 | 31,689,000 | |
| 2021-12-31 | 10-K | -93,063,000 | -1.98 | 32,729,000 | 20,806,000 | |
| 2021-09-30 | 10-Q | -37,049,000 | -0.72 | 45,250,379 | 8,482,000 | |
| 2021-06-30 | 10-Q | -117,000 | -0.41 | 18,546,712 | -39,767,000 | |
| 2021-03-31 | 10-Q | -25,489,000 | -0.71 | 6,027,759 | 6,391,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
Keine Insider-Käufe/Verkäufe in den letzten 12 Monaten.
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.